CPT code 1001T represents an autologous cell-based injection procedure in which a provider injects a patient’s own muscle progenitor cells into the external anal sphincter, optionally using ultrasound guidance. The code captures a novel, targeted therapy intended to improve sphincter muscle function and address disorders associated with sphincter weakness. National attention centers on this code because it documents an advanced biologic intervention that intersects specialized outpatient procedural services and emerging regenerative medicine.

This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical and billing overview, payer coverage considerations, common coding relationships, and benchmarks where available. The publication summarizes policy updates or coverage patterns relevant to advanced regenerative procedures, provides context on typical sites of service and service type, and outlines what to expect in claims processing and documentation requirements. Clinical context explains the intended therapeutic target and procedural setting to help coding, billing, and policy teams align documentation with payer expectations.

Data not available in the input is noted where specific payer policies, modifiers, taxonomies, ICD-10 mappings, and related codes would normally be detailed.